AGS Transact Tech: Investors lose over 65% of their wealth since listing; what lies ahead?

Investors who bought shares in the IPO for ₹175 each and stayed invested up to this point have seen their wealth dwindle by 66.5%. In 2022, the stock lost 63% of its value, positioning it as one of the worst-performing IPOs last year.

33 of 49 SME IPOs in 2023 so far trading above the offer price: Report

A recent report by Moneycontrol informed that SMEs (small &amp; medium enterprises) mopped up ₹930 crore by way of 49 offerings in 2023 so far.

JSW Infrastructure files DRHP to raise ₹2,800 crore via IPO; details here

<ul><li>JSW Infrastructure will be the third company of the JSW Group to be listed on the bourses after JSW Energy and JSW Steel.</li></ul>

New Listing: Mankind Pharma makes stellar debut, lists at ₹1300, over 20% premium to IPO price; should you still buy?

The ₹4,326 crore IPO of Mankind Pharma, which was completely an offer for sale (OFS), was opened for subscription between April 25-27 with a price band of ₹1,026-1,080 per share.

First retail REIT IPO opens today: Should you subscribe to Nexus Select Trust?

Nexus is India's first REIT IPO and the third REIT to be sponsored by Blackstone. Also, Nexus is the first RIET in the Indian retail consumption space.

Nexus Select Trust IPO to open on May 9: Price band, issue size and other details

<ul><li>According to the offer document, the total size of the public issue is ₹3,200 crore, which includes fresh issue of units worth up to ₹1,400 crore and offer for sale (OFS) of up to ₹1,800 crore.</li></ul>

Tata Play's confidentially filed IPO gets market regulator Sebi's go-ahead: Report

Sebi, on April 26, issued its observation letter on the company’s pre-filed offer document. Tata Play will be the first company from the group to launch an IPO in 18 years, noted the report.

Mankind Pharma IPO subscribed 15.32 times on last day of offer

<ul><li>The IPO received bids for 42,95,12,902 shares against 2,80,41,192 shares on offer, according to NSE data.</li></ul>

Mankind Pharma IPO receives 87% subscription on Day 2; QIB portion booked 1.86 times

<ul><li>The IPO received bids for 2,45,19,352 shares against 2.80 crore shares on offer, according to NSE data.</li></ul>

Mankind Pharma IPO: Should you subscribe to the new issue? Brokerages suggest this

Most brokerages have advised 'subscribing' to the issue on the back of market leadership, brand recognition, good financial performance and a strong distribution network, among others.

Top Ipos News

markets

AGS Transact Tech: Investors lose over 65% of their wealth since listing; what lies ahead?

markets

markets

markets